Alpha Tau Medical Ltd. — Form 6-K Summary
Business Context and Reporting Period
Alpha Tau Medical Ltd. filed this Form 6-K as a foreign private issuer for November 2023. The filing reports actions taken at the company’s November 1, 2023 Annual General Meeting of Shareholders.
Key Financial Metrics
The filing does not provide revenue, profitability, cash flow, margins, debt, liquidity, balance-sheet data, or other financial metrics.
Material Changes Versus the Prior Comparable Period
The filing does not report operating or financial changes versus a prior period. It records the re-election of David Milch and Ruth Alon as Class II directors, with terms extending until the 2026 annual general meeting, subject to earlier vacancy or successor qualification.
Guidance, Outlook, Risks, and Unusual Items
- Shareholders approved the re-appointment of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as the independent registered public accounting firm for the year ending December 31, 2023 and until the next annual general meeting.
- The board, with delegation permitted to the audit committee, was authorized to determine the auditors’ fees.
- All proposals received the required majorities under Israeli law and the company’s amended and restated articles.
- The filing contains no new guidance, forecast, material risk disclosure, contingency, or unusual financial item.
- The Form 6-K is incorporated by reference into the company’s specified Form F-3 and Form S-8 registration statements.
Investor Verification Items
- Verify the final voting results and the terms of the Class II director appointments in the referenced proxy statement.
- Confirm the company’s 2023 audited financial results and auditor’s report in the applicable Form 20-F.
- Review the incorporated registration statements for any offering, dilution, or securities-registration implications.